We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Thermo Fisher to Acquire Life Technologies for USD 13.6 Billion

By LabMedica International staff writers
Posted on 22 Apr 2013
Thermo Fisher Scientific (Waltham, MA, USA) and Life Technologies Corporation (Carlsbad, CA, USA) have signed a definitive agreement under which Thermo Fisher will acquire Life Technologies, creating enhanced capabilities for serving life science research, specialty diagnostics, and applied markets. More...
The acquisition will take place for approximately USD 13.6 billion (plus the assumption of net debt at close—USD 2.2 billion as of yearend 2012).

The transaction will create a superior industry leader by building on both companies’ strengths for life sciences, such as proteomics, genomics, and cell biology. It will also strengthen technology and innovation leadership through complementary offerings that further broaden Thermo Fisher’s portfolio. Life Technologies provides innovative services and products (about 5,000 patents and licenses), offering a broad range of reagents, consumables, instruments, and systems. Life has an extensive offering of consumables for genomics, and molecular and cell biology and a range of technologies for bioproduction and forensics; it is also well known for its next-generation sequencing capability. These strengths, combined with Thermo Fisher’s leading offerings in analytical technologies and specialty diagnostics, create new convergence opportunities. The acquisition also enhances Thermo Fisher’s global reach. Life transacts more than half of its orders online through a highly regarded e-commerce platform. This leading capability, combined with Thermo Fisher’s extensive customer channels, creates a world-class infrastructure.


“This transaction enhances [...] our growth strategy: technological innovation, a unique customer value proposition, and expansion in emerging markets,” said Marc N. Casper, president and CEO of Thermo Fisher Scientific. Gregory T. Lucier, chairman and CEO of Life Technologies, said, “We look forward to joining forces with the outstanding team at Thermo Fisher, which shares our commitment to customers, employees, and the communities we serve.” Mr. Casper added, “Together we will be in an even stronger position to fulfill our company’s mission, which is to enable our customers to make the world healthier, cleaner, and safer.”

Related Links:

Thermo Fisher Scientific
Life Technologies



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR Setup
ESTREAM
New
Gold Member
Pipette Management Software
VIALINK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.